These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: IncRNA KTN1-AS1 Silencing Inhibits Non-Small-Cell Lung Cancer Cell Proliferation and KTN1-AS1 Expression Predicts Survival.
    Author: Wu F, Wang L, Xu L, Song S, Liang M.
    Journal: Crit Rev Eukaryot Gene Expr; 2022; 32(2):39-46. PubMed ID: 35381130.
    Abstract:
    Long noncoding RNA (lncRNA) KTN1 antisense RNA 1 (KTN1-AS1) has been characterized as an oncogenic lncRNA in liver cancer. In this study, we investigated the functions of KTN1-AS1 in non-small-cell lung cancer (NSCLC). A total of 66 patients (27 females and 39 males, 28 to 67 years old, mean age 47.1 ± 6.6 years) with NSCLC were enrolled in this study. KTN1-AS1 and CDK1 expression in tissue samples of NSCLC patients were analyzed using reverse transcription quantitative polymerase chain reaction (RT-qPCR). Cell cycle progression assay and cell proliferation assay were performed to analyze the role of KTN1-AS1 in cell cycle progression and cell proliferation. RT-qPCR and Western blot analyses of cells with overexpression were performed to analyze the role of KTN1-AS1 in CDK1 expression. KTN1-AS1 was upregulated in NSCLC tissues and its expression level was positive correlated with CDK1 expression. KTN1-AS1 expression was not changed with clinical stages increasing, and higher KTN1-AS1 levels were associated with poor survival of NSCLC patients. KTN1-AS1 silencing induced G1 phase cell cycle arrest of NSCLC cells and downregulated CDK1. Moreover, KTN1-AS1 silencing suppressed NSCLC cell proliferation and CDK1 overexpression attenuated the effects of KTN1-AS1 silencing on cell proliferation. KTN1-AS1 may regulate cell cycle progression in NSCLC by regulating CDK1.
    [Abstract] [Full Text] [Related] [New Search]